济民医疗(603222) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the year-to-date reached CNY 192,878,575.35, representing a 17.40% increase year-on-year[7] - Net profit attributable to shareholders was CNY 11,261,381.66, a slight increase of 0.42% compared to the same period last year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 19.09% to CNY 8,841,806.45[7] - The weighted average return on equity decreased by 0.02 percentage points to 1.38%[7] - Total operating revenue for Q1 2019 was CNY 192,878,575.35, an increase of 17.4% compared to CNY 164,295,406.81 in Q1 2018[25] - Net profit for Q1 2019 reached CNY 13,596,802.12, representing a 15.3% increase from CNY 11,794,753.75 in Q1 2018[26] - Total operating costs for Q1 2019 were CNY 177,809,918.15, up from CNY 148,328,893.59 in Q1 2018, reflecting a growth of 19.9%[25] - Operating profit for Q1 2019 was a loss of CNY 3,662,221.99, compared to a loss of CNY 1,424,889.44 in Q1 2018[31] - Net profit for Q1 2019 was a loss of CNY 2,782,503.92, worsening from a loss of CNY 1,737,238.44 in Q1 2018[31] - Total comprehensive income for Q1 2019 was a loss of CNY 2,782,503.92, compared to a loss of CNY 1,737,238.44 in Q1 2018[31] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 5,775,207.01, a significant improvement from a negative cash flow of CNY 47,134.52 in the same period last year[7] - Cash received from operating activities rose by 202.63% to ¥4,514,644.21, mainly due to increased guarantees received[13] - In Q1 2019, the company reported a net cash inflow from operating activities of CNY 21,851,810.01, an increase of 11.8% compared to CNY 19,547,473.36 in Q1 2018[36] - The company's total cash inflow from operating activities was CNY 47,793,596.45, down from CNY 61,849,721.08 in the previous year, reflecting a decrease of 22.7%[36] - The company reported a net decrease in cash and cash equivalents of CNY 17,701,790.60 in Q1 2019, contrasting with a net decrease of CNY -69,991,563.35 in Q1 2018[34] Assets and Liabilities - Total assets increased by 1.30% to CNY 2,152,547,903.69 compared to the end of the previous year[7] - Total liabilities as of March 31, 2019, were ¥1,093,729,226.41, compared to ¥1,078,245,914.35 at the end of 2018[18] - Total liabilities decreased to CNY 622,604,196.85 from CNY 630,847,686.89 at the end of 2018, a reduction of 1.8%[23] - The company's total assets as of March 31, 2019, amounted to CNY 1,300,109,966.67, slightly down from CNY 1,311,135,960.63 at the end of 2018[22] - Current liabilities reached CNY 685,786,220.89, including short-term borrowings of CNY 270,000,000.00 and accounts payable of CNY 254,509,895.45[39] - Total liabilities were CNY 1,078,245,914.35, with non-current liabilities at CNY 392,459,693.46[40] Shareholder Information - The number of shareholders at the end of the reporting period was 8,131[11] - The largest shareholder, Shuangge Group Co., Ltd., held 36.20% of the shares, with 115,830,800 shares pledged[11] Expenses - Management expenses increased by 31.91% to CNY 19,093,609.56 due to the consolidation of new hospitals[12] - Financial expenses increased by 58.68% to ¥7,148,877.65 due to increased borrowings[13] - Cash paid for purchasing goods and services increased by 37.64% to ¥79,449,867.83, attributed to the consolidation of new hospitals[13] - Cash paid to employees increased by 41.97% to ¥45,973,914.72, also due to the consolidation of new hospitals[13] - Research and development expenses for Q1 2019 were CNY 4,418,752.74, compared to CNY 3,977,050.26 in Q1 2018, marking an increase of 11.1%[26] - Financial expenses rose significantly to CNY 6,344,593.43 in Q1 2019, compared to CNY 3,222,945.20 in Q1 2018, marking an increase of 97.5%[30] Other Income - Other income surged by 283.39% to ¥3,029,650.67, primarily from increased subsidies[13] - The company reported a significant increase in interest income to CNY 432,927.48 in Q1 2019, up from CNY 77,565.35 in Q1 2018[31]